Approved for use through 10/31/2002. OMB 0o51-0031 a
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
in of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no per Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE TO pplication Number 09/872,698 Filing Date June 1, 2001 STATEMENT BY APPLICANT First Named Inventor Elsberry (use as many sheets as necessary) Group Art Unit 3763 Examiner Name Unknown Sheet of 2 Attorney Docket Number P-3226.04

	Cite	U.S. Patent Document	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initiate*		Number (if kr	Code <sup>2</sup> Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
4	1	3,894,541	El-Shafei	07/15/1975		
///		3,941,119	Corrales	03/02/1976	·	
J		4,613,324	Ghajar	09/23/1986		
		4,670,313	Saudagar	06/02/1987		
		4,686,085	Osterholm	08/11/1987		
,		4,710,181	Fuqua	12/01/1987		
		4,767,400	Miller et al.	08/30/1988		
		4,781,672	Hooven	11/01/1988		
		4,998,938	Ghajar et al.	03/12/1991		
$\neg \tau$		5,169,387	Kronner	12/08/1992		
$\neg \vdash$		5,180,387	Ghajar et al.	01/19/1993		
$\neg \vdash$		5,192,753	McGeer et al.	03/09/1993		
		5,385,541	Kirsch et al.	01/31/1995		
		5,399,346	Anderson et al.	03/21/1995		
		5,405,316	Magram	04/11/1995		
$\neg$		5,468,221	Schöner	11/21/1995		
		5,478,807	Cronin et al.	12/26/1995		
		5,542,935	Unger et al.	08/06/1996		
		5,552,415	May	09/03/1996		
T		5,643,207	Rise	07/01/1997		
		5,683,357	Magram	11/04/1997	-4	
		5,728,061	Ahmed	03/17/1998	6	
		5,756,553	Iguchi et al.	05/26/1998	37	
		5,772,261	Magram	06/30/1998	00 7	
		5,846,220	Elsberry	12/08/1998	, ,	
		5,880,116	Vigo-Pelfrey	03/09/1999		
		5,895,378	Berenstein et al.	04/20/1999	F 28	
1		6,056,725	Elsberry	05/02/2000	1, 5	
	Ī	6,140,116	Dinsmore	10/31/2000	8-	

<del></del>		FOREIGN PATENT DOCUMENTS    Date of Publication   Date of Publicat				Pages Columns Lines Where		
Examiner Initials*	Cite No.	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee of Applicant of Cited Document	of Cited Document MM-DD-YYYY	Pages, Columna, Lines, Where Relevant Pissages or Relevant Figures Appear	Τ*
							<u> </u>	-
			AI	11				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw Line through citation if not in conformance and not considered. Include copy of this form with next co ation to applican

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FRES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unique citation designation nu

Offique cranion designation number.

3 See attached Kinds of U.S. Patent Documents.

3 Enter Office that issued the document, by the two-letter code (WIPO Standard St.3).

4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5 Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 16 if possible.

6 Applicant is to place a check mark here if English language Translation is attached.

of 2

Sheet 2



Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

to respond to a collector of information of the collection of the Under the Paperwork Reduction Act of 1995, no persons are red information unless it contains a valid OMB control number. Substitute for form 1449B/PTO Complete if Known 09/872,698 INFORMATION DISCLOSURE Filing Date June 1, 2001 STATEMENT BY APPLICANT First Named Inventor Elsberry Group Art Unit 3763 (use as many sheets as necessary) Examiner Name Unknown

Attorney Docket Number

P-3226.04

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
examiner nitials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
		publisher, city and/or country where published.	<u> </u>
	hn .	Dorland's Illustrated Medical Dictionary, W.B. Saunders Company, p. 189.	
1		Breitner, J.C.S. et al., "Inverse Association of Anti-Inflammatory Treatments and Alzheimer's Disease: Initial Results of a Co-Twin Control Study", Neurology, Vol. 44, pp. 227-232 (February, 1994).	
~		Duong, Taihung et al., "Microtubule-association Proteins Tau and Amyloid P Component In Alzheimer's Disease", Brain Research, Vol. 608, pp. 74-86 (1993).	
		Eikelenboom, Piet et al., "Inflammatory Mechanisms In Alzheimer's Disease", TiPs, Vol. 15, pp. 447-450 (December 1994).	
$\top$		Forloni, Gianluigi et al., "Expression of Amyloid Precursor Portein mRNAs in Endothelial, Neuronal and Glial Cells: Modulation By Interleukin-1", Molecular Brain Research, Vol. 16, pp. 128-133 (1992).	
$\exists$		Malmberg, A.B. et al., "Hyperalgesia Mediated by Spinal Glutamate or Substance P Receptor Blocked by Spinal Cyclooxygenase Inhibition", Science, Vol. 257, pp. 1276-1279 (August 28, 1992).	
$\top$		Meade, E.A. et al., "Differential Inhibition of Prostaglandin Endoperoxide Synthase (Cyclooxygenase) Isozymes by Aspirin and Other Non-steroidal Anti-inflammatory Drugs", Vol. 268, No. 9, pp.6610-6614 (March 25, 1993).	
$\top$		Mitchell, J.A. et al., "Selectivity of Nonsteroidal Antiinflammatory Drugs as Inhibitors of Constitutive and Inducible Cyclooxygenase", <i>Proceedings of the National Academy of Sciences</i> , Vol. 90, No. 24, pp. 1693-11697 (December 15, 1993).	
T		Murphy, M., "The Molecular Pathogenesis of Alzheimer's Disease: Clinical Prospects", Vol. 340, pp. 1512-1515 (December 19/26, 1992).	
T		Netland, E.E. et al., "Indomethacin Reverses B-amyloid Induced Gliosis", Department of Psychiatry and Human Behavior, Miriam Hospital and Brown University Medical School, 11 pgs. (Date Unknown).	
1		Netland, E., "Neuropathological and Cognitive Impairment in an Animal Model of Alzheimer's Disease", Bachelor of Science with Distinction in the Neuroscience Concentration Thesis, Brown University, 55 pgs. (April 21, 1995).	
$\top$		Rich, J.B. et al., "Nonsteroidal Anti-inflammatory Drugs in Alzheimer's Disease", Neurology, Vol. 45, pp. 51-55 (January 1995).	
1		Rogers, J. et al., "Clinical Trial of Indomethacin in Alzheimer's Disease", Neurology, Vol. 43, pp. 1609-1611 (August 1993).	
		Schnabel, J., "New Alzheimer's Therapy Suggested", Science, Vol. 260, pp. 1719-1720 (June 18, 1993).	
		Soukas, A.A., "Screening of a Possible Therapeutic Agent For Alzheimer's Disease", Biomedical Engineering Concentration of Brown University Thesis, 54 pgs. (April 28, 1995).	-
		Tate, B.A. et al., "Continuous ICV Infusion of Synthetic B-amyloid Peptide: Potential Model For Amyloid Depositions", Dept. of Psychiatry and Human Behavior, The Miriam Hospital, Providence, Rhode Island 02906 (Date Unknown).	
<u> </u>			
		3	
		37.0	出一
			2
		3700 MA	
			8
			<u>K</u>
			<u></u>
xamine ignatur		Date Considered 9/27/01	

\*EXAMINER: Initial it reference considered, who her or not citation is in conformance with MPEP 609. Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FLES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unique citation designation number.

Applicant is to place a check mark here if English language Translation is attached.